Regeneron Pharmaceuticals (WBO:REGN) Other Current Liabilities : €0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Regeneron Pharmaceuticals Other Current Liabilities?

Regeneron Pharmaceuticals's other current liabilities for the quarter that ended in Dec. 2023 was €0 Mil.

Regeneron Pharmaceuticals's quarterly other current liabilities increased from Jun. 2023 (€-0 Mil) to Sep. 2023 (€0 Mil) and increased from Sep. 2023 (€0 Mil) to Dec. 2023 (€0 Mil).

Regeneron Pharmaceuticals's annual other current liabilities declined from Dec. 2021 (€0 Mil) to Dec. 2022 (€-680 Mil) but then increased from Dec. 2022 (€-680 Mil) to Dec. 2023 (€0 Mil).

Regeneron Pharmaceuticals Other Current Liabilities Historical Data

The historical data trend for Regeneron Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Other Current Liabilities Chart

Regeneron Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

Regeneron Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

Regeneron Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Regeneron Pharmaceuticals Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Regeneron Pharmaceuticals (WBO:REGN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (WBO:REGN) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

REGN:USA REGN:Mexico RGO:Germany REGN34:Brazil

Address

777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707

Website

https://www.regeneron.com

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).